Quantcast

Latest Frovatriptan Stories

2014-07-22 08:31:00

MONMOUTH JUNCTION, N.J., July 22, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their US prescription cough cold collaboration. Under this collaboration, POC requires the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. As a result of achieving POC,...

2014-04-11 08:24:31

PITTSBURGH, April 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. This product is the generic version of FROVA(®), which is used to treat acute...

2014-02-11 12:22:18

DUBLIN, Feb. 11, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/b9xkxb/triptans) has announced the addition of the "Concise Analysis of the International Triptans Products, Pipelines, Players, Patents and Prospects" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Triptans consist of a class of drugs called selective 5-hydroxytryptamine subtype 1 (5-HT1) receptor agonists. Migraine headaches are an established and...

2014-01-29 16:28:52

MALVERN, Pa., Jan. 29, 2014 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP) today confirmed that the United States District Court for the District of Delaware ruled that United States Patent No. 5,464,864, Endo's patent covering frovatriptan, the active ingredient in FROVA(® )(frovatriptan succinate) tablets, is valid and infringed. The Court's decision prevents Mylan from marketing its generic version of FROVA(®) in the U.S. before Endo's patent expires November 8, 2015,...

2011-08-17 06:50:00

PITTSBURGH, Aug. 17, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Endo Pharmaceuticals in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate EQ, 2.5 mg base tablets. This product is the generic version of Frova®, which is indicated for the treatment of symptoms associated with...

2010-07-20 15:30:00

CHADDS FORD, Pa., July 20 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) will announce its second quarter 2010 financial results on July 30, 2010 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results. David P. Holveck, president and CEO of Endo, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, and Alan Levin, executive vice president and chief financial officer and Blaine Davis, vice...

2010-06-11 15:05:00

UNION CITY, Calif., June 11 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has received notification from the U.S. Food & Drug Administration (FDA) that the PDUFA date for Questcor's supplemental new drug application (sNDA) to approve Acthar for the treatment of infantile spasms (IS) has been extended to September 11, 2010. The FDA extended the PDUFA date in order to review information regarding labeling and potential post-approval...

2010-03-17 08:00:00

CHADDS FORD, Pa., March 17 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, Mar. 23, 2010, at 10:15 a.m. EDT. David Holveck, president and chief executive officer of Endo, will review the company's products and development programs. The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section. About Endo...

2009-08-12 07:30:00

CHADDS FORD, Pa., Aug. 12 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the resignation of Nancy Wysenski, Endo chief operating officer, effective September 1, to attend to family matters. David Holveck, Endo's president and chief executive officer, stated: "I thank Nancy Wysenski for her contributions to the successful transition of Endo over the past two years. She has been instrumental in supporting our strong revenue growth, the diversification of the...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related